Pharmacy Billing Services · 2026 Payer Update

The Part D redesign stops being policy and starts being your remittance in 2026.

The Inflation Reduction Act rebuilt the Medicare Part D benefit on paper in 2025. In 2026 it lands where it actually costs you money: the point of sale, the reconciliation file, and the retro refund you are still chasing 30 days later.

The short answer: the same fill now reconciles through three ledgers at once. A national Part D layer (the $2,100 out-of-pocket cap, Maximum Fair Prices on the first 10 negotiated drugs, and the Manufacturer Discount Program), a state Medicaid layer (NADAC plus a professional dispensing fee that changes at every state line), and a 340B layer with its own ceiling price and duplicate-discount rules. Get your posting logic aligned to all three, or watch clean claims underpay quietly.

SOURCES NAMED BELOW: IRA Part D Benefit Redesign · CMS CY2026 Part D Redesign Program Instructions · Medicare Drug Price Negotiation Program (MFP) · NCPDP Telecommunication Standard D.0 · 42 CFR 447.512 / 447.518 · Section 340B PHSA

What actually changed at the counter

Four numbers your pharmacy team feels in 2026

None of these are new laws. They are the 2026 operational face of the redesign, and each one moves a dollar figure on the claim you already submit today.

$2,100

Annual Part D out-of-pocket cap for CY2026, indexed up from the $2,000 cap that began in 2025.

IRA / CMS CY2026

First negotiated Part D drugs whose Maximum Fair Price takes effect January 1, 2026, reimbursed through the Medicare Transaction Facilitator.

Drug Price Negotiation

10/20%

Manufacturer Discount Program share in the initial coverage and catastrophic phases, replacing the old Coverage Gap Discount Program.

Section 11201 IRA

What the pharmacy fronts under the Medicare Prescription Payment Plan. The plan pays you in full at point of sale; the member smooths their cost over the year.

M3P Smoothing

The redesigned benefit, drawn to scale

Three phases now, no coverage gap

The donut hole is gone. Every Part D claim in 2026 lands in one of three phases, and the phase decides who pays which share, which changes how your point-of-sale reimbursement and your downstream reconciliation should read.

Where a 2026 fill sits in the benefit

Illustrative widths show relative member exposure, not exact dollar bands.

Phase 1Deductible

Phase 2Initial coverage · Manufacturer Discount 10%

Phase 3Catastrophic · $0 member · Mfr 20%

$2,100 hard out-of-pocket cap. Once the member hits it, they owe $0 for covered Part D drugs for the rest of the year.

CMS CY2026 Part D Redesign Program Instructions

2025 built it · 2026 bills it

The counter-level change happens this year

2025 FOUNDATION

$2,000 out-of-pocket cap goes live; the coverage gap is eliminated.
Manufacturer Discount Program replaces the Coverage Gap Discount Program.
Medicare Prescription Payment Plan opens for member opt-in.
Plans and PBMs restructure their Part D reimbursement math.

2026 AT THE COUNTER

Cap indexes to $2,100 for the new plan year.
Maximum Fair Prices for the first 10 negotiated drugs take effect Jan 1.
Pharmacies reconcile MFP reimbursement through the Medicare Transaction Facilitator, with manufacturer payment expected within 14 days.
M3P is in full swing: correct at point of sale, watch the member-billing hand-off.

The angle nobody prices in

One national redesign, fifty state reconciliations

The Part D layer is national. The layer underneath it is not. Under the CMS Covered Outpatient Drug rule (42 CFR 447.512 and 447.518), each state Medicaid program sets its own professional dispensing fee from its own cost-of-dispensing survey, and each sets its own 340B carve-in or carve-out policy in managed care. Stack those on the same molecule and the same fill reconciles differently at every state line.

Tier 1 · dispensing fee + NADAC Tier 2 · + managed-care 340B policy Tier 3 · + carve-in and MFP overlap

Tiers are an illustrative teaching device for reconciliation load, not per-state billing values. Confirm the actual professional dispensing fee in each state's CMS-approved State Plan Amendment and the 340B carve-in / carve-out rule in each state's Medicaid provider manual before you post.

One fill, three ledgers

Why the same NDC reconciles three different ways

Take a single dual-eligible fill of a negotiated drug at a 340B contract pharmacy. That one transaction has to close cleanly against all three of these at once.

Point of sale

One fill

Negotiated Part D drug, dual-eligible member, dispensed by a 340B contract pharmacy.

🌐

Part D national layer

Maximum Fair Price applies, the member cost counts toward the $2,100 cap, and MFP reimbursement flows back through the Medicare Transaction Facilitator, not the plan check.

Medicare Drug Price Negotiation Program · MTF

🏙

State Medicaid layer

Ingredient cost pays at NADAC plus that state's professional dispensing fee, and Medicaid crossover logic decides the wrap on the dual-eligible balance.

42 CFR 447.512 / 447.518 · NADAC

🛡

340B layer

The 340B ceiling price sets acquisition, and the duplicate-discount prohibition means the claim must be identified correctly so the state does not also invoice a Medicaid rebate on the same unit.

Section 340B PHSA · duplicate-discount rule

It all rides on one message format

The NCPDP claim is where these layers collide

Every one of these programs is carried by the NCPDP Telecommunication Standard. If the flags and coordination-of-benefits data are wrong on the way out, the reconciliation is wrong on the way back.

NCPDP D.0

Coordination of benefits

The Other Coverage Code and the Other Payer segments drive the dual-eligible wrap. A miskeyed value here is the most common quiet Medicaid crossover underpayment.

340B identification

Submission clarification

340B claims must be flagged so states can exclude them from rebate invoicing. Missing that identifier is how a duplicate discount, and a takeback, gets created.

M3P + MFP

New program guidance

NCPDP has published implementation guidance for the Medicare Prescription Payment Plan and for negotiated-price transactions. Your switch and system edits need to match it before Jan 1.

Before and after, in plain terms

What a negotiated-drug fill looks like now

Conceptual comparison for a Part D fill of a drug on the first negotiation list. No client data, illustrative only.

Element	Pre-redesign posture	2026 posture
Drug price basis	Plan-negotiated price only	Maximum Fair Price for negotiated drugs
Where the money comes back	Single plan remittance	Plan remittance plus MTF manufacturer reimbursement
Member exposure	Coverage gap, open-ended spend	Hard $2,100 cap, then $0
Manufacturer share	Coverage Gap Discount Program	Manufacturer Discount Program, 10% / 20%
Member payment timing	Full cost at the counter	Optional M3P smoothing, plan pays pharmacy in full
State layer	Same NADAC + dispensing fee	Same, but now stacked under MFP and 340B checks

Where the revenue leaks

Four ways this quietly underpays a clean claim

Unposted MTF reimbursement.

The plan check and the manufacturer refund arrive on different clocks. If your posting only reconciles the plan side, the MFP piece ages unmatched.

Duplicate-discount takebacks.

A 340B claim that was not identified correctly invites a Medicaid rebate on the same unit, and the recovery lands on you months later.

Wrong-state dispensing fee.

A multi-state operation posting one blended fee will over-post in low-fee states and under-post in high-fee states, every single day.

Broken M3P hand-off.

The plan pays you in full, but the member balance moves to a smoothing invoice. Treat that member balance like normal AR and you will chase money that was never owed to you.

Reconcile all three ledgers on the same fill.

ASP-RCM Solutions builds pharmacy billing and reconciliation logic that reads the Part D redesign, the state Medicaid layer, and 340B as one transaction, so MFP refunds get posted, 340B claims stay clean, and dispensing fees match the state you actually filled in.

Map your 2026 reconciliation →

We work the NCPDP edits, the MTF matching, and the state-by-state fee tables so your clean claims stay clean. Tell us where your fills cross state lines, and we will show you where the same molecule is reconciling three different ways.